Prostate cancer is the most common cancer in men in the UK with around 43,000 new cases diagnosed in 2012
(Cancer Research, UK). By 2030, it is predicted that this will be the most common cancer of all (Mistry, 2011). The exponential increase of prostate cancer over the last 40 years is attributed to widespread uptake of the prostate-specific androgen (PSA) test in primary care. Because of this, many prostate cancers are being diagnosed and treated in their very early stages, and subsequently men are living for many years following treatment, or living with indolent disease that will never require treatment in their natural lifespan. As a result, around 84% of men survive for 10 years or more. Prostate cancer has indeed become a ‘long-term condition’.